Publication: Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells
dc.contributor.author | Dikmen, Gökhan | |
dc.contributor.author | Genç, Lütfi | |
dc.contributor.buuauthor | Güney, Gamze | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Tıbbi Biyoloji Ana Bilim Dalı | |
dc.contributor.orcid | 0000-0002-2088-9914 | |
dc.contributor.researcherid | AAB-6011-2022 | |
dc.contributor.scopusid | 54396977600 | |
dc.date.accessioned | 2024-03-14T12:53:13Z | |
dc.date.available | 2024-03-14T12:53:13Z | |
dc.date.issued | 2015 | |
dc.description.abstract | Many anticancer drugs that are currently used in cancer treatment are natural products or their analogues by structural modification. Caffeic acid (3, 4-dihydroxycinnamic acid; CA) is classified as hydroxycinnamic acid and has a variety of potential pharmacological effects, including antioxidant, immunomodulatory and anti-inflammatory activities. As a drug carrier, solid lipid nanoparticles (SLNs) introduced to improve stability, provide controlled drug release, avoid organic solvents and are obtained in small sizes. In this study, we developed solid lipid nanoparticles incorporating with caffeic acid using hot homogenization method. Caffeic acid loaded solid lipid nanoparticles were characterized regarding particle size, zeta potential, drug entrapment efficiency, drug release, scanning electron microscopy (SEM) and FT-IR. The effects of caffeic acid loaded solid lipid nanoparticles on MCF-7 cells were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-dimethyl tetrazolium bromide (MTT) test and Annexin V-PI analysis. As a result, solid lipid nanoparticles could potentially be used for the delivery of caffeic acid and solid lipid nanoparticles formulation enhanced the effects of caffeic acid on MCF-7 cells. Some relevant patents are also referred in this article. | |
dc.identifier.citation | Dikmen, G. vd. (2015). "Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells". Recent Patents on Anti-Cancer Drug Discovery, 10(2), 224-232. | |
dc.identifier.doi | https://doi.org/10.2174/1574892810666150115124413 | |
dc.identifier.endpage | 232 | |
dc.identifier.issn | 1574-8928 | |
dc.identifier.issn | 2212-3970 | |
dc.identifier.issue | 2 | |
dc.identifier.pubmed | 25619199 | |
dc.identifier.scopus | 2-s2.0-84930883833 | |
dc.identifier.startpage | 224 | |
dc.identifier.uri | https://www.eurekaselect.com/article/64565 | |
dc.identifier.uri | https://hdl.handle.net/11452/40412 | |
dc.identifier.volume | 10 | |
dc.identifier.wos | 000354364700010 | |
dc.indexed.scopus | Scopus | |
dc.indexed.wos | SCIE | |
dc.language.iso | en | |
dc.publisher | Bentham Science Publisher | |
dc.relation.collaboration | Yurt içi | |
dc.relation.journal | Recent Patents on Anti-Cancer Drug Discovery | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Oncology | |
dc.subject | Pharmacology & pharmacy | |
dc.subject | Apoptosis | |
dc.subject | Caffeic acid (CA) | |
dc.subject | Cancer | |
dc.subject | Characterization | |
dc.subject | Drug delivery systems | |
dc.subject | Solid lipid nanoparticles (SLNs) | |
dc.subject | Phenethyl ester suppresses | |
dc.subject | Microscale drug particles | |
dc.subject | Natural-products | |
dc.subject | Cancer cells | |
dc.subject | SLN | |
dc.subject | Immobilization | |
dc.subject | Proliferation | |
dc.subject | Cytotoxicity | |
dc.subject | Metastasis | |
dc.subject | Inhibition | |
dc.subject.emtree | Caffeic acid | |
dc.subject.emtree | Lipocortin 5 | |
dc.subject.emtree | Solid lipid nanoparticle | |
dc.subject.emtree | Antineoplastic agent | |
dc.subject.emtree | Caffeic acid | |
dc.subject.emtree | Caffeic acid derivative | |
dc.subject.emtree | Delayed release formulation | |
dc.subject.emtree | Drug carrier | |
dc.subject.emtree | Lipid | |
dc.subject.emtree | Nanoparticle | |
dc.subject.emtree | Apoptosis | |
dc.subject.emtree | Article | |
dc.subject.emtree | Breast cancer | |
dc.subject.emtree | Controlled drug release | |
dc.subject.emtree | Controlled study | |
dc.subject.emtree | Drug entrapment | |
dc.subject.emtree | Drug formulation | |
dc.subject.emtree | Drug stability | |
dc.subject.emtree | Hot homogenization method | |
dc.subject.emtree | Human | |
dc.subject.emtree | Human cell | |
dc.subject.emtree | Infrared spectroscopy | |
dc.subject.emtree | MCF 7 cell line | |
dc.subject.emtree | MTT assay | |
dc.subject.emtree | Particle size | |
dc.subject.emtree | Photon correlation spectroscopy | |
dc.subject.emtree | Priority journal | |
dc.subject.emtree | Procedures | |
dc.subject.emtree | Scanning electron microscopy | |
dc.subject.emtree | Zeta potential | |
dc.subject.emtree | Breast neoplasms | |
dc.subject.emtree | Chemistry | |
dc.subject.emtree | Delayed release formulation | |
dc.subject.emtree | Drug delivery system | |
dc.subject.emtree | Female | |
dc.subject.emtree | Medicinal chemistry | |
dc.subject.emtree | Patent | |
dc.subject.emtree | Pathology | |
dc.subject.mesh | Antineoplastic agents | |
dc.subject.mesh | Breast neoplasms | |
dc.subject.mesh | Caffeic acids | |
dc.subject.mesh | Chemistry, pharmaceutical | |
dc.subject.mesh | Delayed-action preparations | |
dc.subject.mesh | Drug carriers | |
dc.subject.mesh | Drug compounding | |
dc.subject.mesh | Drug delivery systems | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lipids | |
dc.subject.mesh | MCF-7 cells | |
dc.subject.mesh | Microscopy, electron, scanning | |
dc.subject.mesh | Nanoparticles | |
dc.subject.mesh | Particle size | |
dc.subject.mesh | Patents as topic | |
dc.subject.mesh | Spectroscopy, fourier transform infrared | |
dc.subject.scopus | Nanocrystal; Tristearin; Polydispersity | |
dc.subject.wos | Oncology | |
dc.subject.wos | Pharmacology & pharmacy | |
dc.title | Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells | |
dc.type | Article | |
dc.wos.quartile | N/A | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/Tıbbi Biyoloji Ana Bilim Dalı | |
local.indexed.at | PubMed | |
local.indexed.at | WOS | |
local.indexed.at | Scopus |
Files
License bundle
1 - 1 of 1
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: